Disc Medicine (IRON) Non-Current Debt (2020 - 2021)
Disc Medicine (IRON) reported Non-Current Debt of $404000.0 for Q4 2021, down 91.84% year-over-year from $5.0 million in Q4 2020, and down 75.47% quarter-over-quarter from $1.6 million in Q3 2021.
Disc Medicine (IRON) Non-Current Debt (2020 - 2021) Analysis & Trends
Disc Medicine (IRON) has 2 years of Non-Current Debt data on file, last reported at $404000.0 in Q4 2021.
- Non-Current Debt for Q4 2021 came in at $404000.0, down 91.84% year-over-year; the trailing twelve-month figure through Dec 2021 was $404000.0 (down 91.84% YoY), and the FY2021 annual result was $404000.0, down 91.84% from the prior year.
- Non-Current Debt eased to $404000.0 in Q4 2021 per IRON's latest filing, from $1.6 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $5.0 million in Q4 2020 and troughed at $404000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Disc Medicine | 2.73 Bn | 2.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 404,000.00 |
| Dec 31, 2021 | 404,000.00 |
| Sep 30, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.65 Mn |
| Jun 30, 2021 | 2.89 Mn |
| Jun 30, 2021 | 2.89 Mn |
| Mar 31, 2021 | 4.13 Mn |
| Mar 31, 2021 | 4.13 Mn |
| Dec 31, 2020 | 4.95 Mn |
| Dec 31, 2020 | 4.95 Mn |